A Tumor-Agnostic NTRK (TRK) Inhibitor
Copyright policy ) Franklin W, Huang; Felix Y, Feng;
A Tumor-Agnostic NTRK (TRK) Inhibitor
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
- University of California, San Francisco United States
Pyrimidines, Oncogene Proteins, Fusion, Neoplasms, Humans, Pyrazoles, Receptor Protein-Tyrosine Kinases, Receptor, trkB, Receptor Tyrosine Kinase-like Orphan Receptors, Protein Kinase Inhibitors
Pyrimidines, Oncogene Proteins, Fusion, Neoplasms, Humans, Pyrazoles, Receptor Protein-Tyrosine Kinases, Receptor, trkB, Receptor Tyrosine Kinase-like Orphan Receptors, Protein Kinase Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).44 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
selected citations
Citations provided by BIP!
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citations provided by BIP!popularityPopularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP! 44
Top 10%
Top 10%
Top 1%
hybrid
